Leader Sequence for Higher Expression of Recombinant Proteins

The present invention relates to the leader sequence for higher expression of recombinant proteins. The invention further relates to the process for preparation of insulin and insulin analogues using leader sequence. The leader peptides significantly increase the expression of pre-proinsulin. The present invention also relates to the protein sequences prepared by fusion of fragments with the leader sequences of the present invention. The invention is demonstrated by preparing and Insulin and its analogues using said leader sequences. 1. A process for producing insulin and insulin analogues comprising pre-proinsulin of Formula 1:{'br': None, 'sub': 1', '1', '2', '3, 'R—X-X-X\u2003\u2003Formula 1'}{'sub': 1', '2', '3', '1, 'as an intermediate, wherein Xis a ‘B’ chain of insulin or insulin analogues, Xis a dipeptide selected from RR or KR or RK or KK, Xis an ‘A’ chain of insulin or insulin analogues and Ris a leader peptide sequence selected from'}a) a peptide having amino acid sequence as set forth of in SEQ ID NO: 2 orb) a peptide having at least 80% homology to a).2. The process as claimed in claim 1 , wherein the leader peptide having at least 80% homology is selected from:a) a peptide having amino acid sequence as set forth in SEQ ID NO: 1,b) a peptide comprising amino acid sequence of: MSRIVINAYAKATQP;c) a peptide comprising amino acid sequence of: MEKHTKDQIIEAPHM.3. The process as claimed in claim 1 , wherein the process comprises preparation of proinsulin of Formula 2: X-X-Xfrom pre-proinsulin claim 1 , wherein Xis a ‘B’ chain of insulin or insulin analogues claim 1 , Xis a dipeptide selected from RR or KR or RK or KK claim 1 , and Xis an ‘A’ chain of insulin or insulin analogues.4. The process as claimed in claim 3 , wherein the process comprises expression of proinsulin by culturing prokaryotic host cells comprising a nucleic acid encoding proinsulin operably linked to the leader peptide in a production medium.5PseudomonasEscherichia coli. The process as ...

REDIRECTING TO A TRUSTED DEVICE FOR SECURED DATA TRANSMISSION

In various example embodiments, a machine is configured to redirect completion of a transaction to a trusted device. For example, the machine determines that a page involving the transaction is being displayed in a user interface of a first device. The page may be associated with the product or service. The machine identifies an interruption of the displaying of the page in the user interface of the first device. The machine identifies a second device that is trusted by the user. The machine transmits a communication including a notification to the second device. The notification indicates the transaction. 1. A method comprising:causing display of a user interface on a first device associated with a user, the user interface including an input element for identification of trusted devices for use in transactions;receiving, from the first device, an identifier of a trusted device via the input element included in the user interface;determining, using one or more hardware processors, that the identifier of the trusted device is different from an identifier of the first device;associating the identifier of the trusted device with an identifier of the user in a database record; andcausing display, in the interface of the first device, of a notification pertaining to a transaction, the notification including the identifier of the trusted device.2. The method of claim 1 , further comprising:causing display of a payment page for a purchase of a product or service in a user interface of the trusted device.3. The method of claim 2 , further comprising:facilitating a payment by the user for the product or service from the trusted device without additional authentication of the user.4. The method of claim 1 , further comprising:determining that a payment page for a purchase of a product or service is being displayed in the user interface of the first device;detecting an interruption of the display of the payment page in the user interface of the first device; andcausing display ...

ASSAY INFORMATION MANAGEMENT METHODS AND DEVICES

The present invention relates to methods, devices and systems for associating assay information with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system includes a reader adapted to read/erase/write information from/to an assay consumable identifier associated with the assay consumable. Various types of assay information are described, as well as methods of using such information in the conduct of an assay by an assay system.

RATE-LIMITING BASED ON CARDINALITY COMPUTATION

A cloud-based service records time-series data of a plurality of metrics from a plurality of tenants. The time-series data comprises a series of measures of a metric at sequential points in time. The time-series data is recorded in database tables in a manner that consumes more resources when the cardinality of the time-series data is high. When the cardinality of the data for the tenant is too high, the tenant is blacklisted and further data for the tenant is not stored. In addition to identifying incoming time-series data by the tenant that produced it, the data may also identify its type. In this case, the cardinality of each type of data may be determined and the types of data may be individually allowed or blacklisted for the tenant. 1. A system comprising:a memory that stores instructions; and serially receiving a plurality of data from a set of devices that is part of a tenant of a cloud-based service;', 'storing the plurality of data in a database;', 'determining a cardinality of the plurality of data; and', 'based on the cardinality and a predetermined threshold, blocking at least some further data from the set of devices., 'one or more processors configured by the instructions to perform operations comprising2. The system of claim 1 , wherein the operations further comprise:serially receiving a second plurality of data from a second set of devices;determining a second cardinality of the second plurality of data; andbased on the second cardinality and a second predetermined threshold, storing second further data from the second set of devices while blocking the at least some further data from the set of devices.3. The system of claim 1 , wherein:the serially receiving the plurality of data from the set of devices comprises serially receiving a first plurality of data associated with a first identifier;the determining of the cardinality of the plurality of data comprises determining a first cardinality for the first identifier;the blocking of the at least ...

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises MDC, NME-2, KGF, PlGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, Amy1A, MIP-1b, P-Cadherin, EPO, and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.2. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer , said method comprising(a) ordering a test comprising a measurement of a level of a biomarker in a test sample obtained from a patient undergoing said treatment regimen for lung cancer, wherein said biomarker comprises MDC, NME-2, KGF, PlGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, Amy1A, MIP-1b, P-Cadherin, EPO, and combinations thereof;(b) comparing said level to a normal control level of said biomarker; and(c) evaluating from said comparing step (b) whether said patient is responsive to said treatment regimen.3. A method of administering a treatment regimen to a patient in need thereof for treating lung cancer , comprising:(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises ...

Assay Cartridges and Methods of Using the Same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge.

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Assay cartridges and methods of using the same

Assay cartridges are described that have purification, reaction, and detection zones and other fluidic components which can include sample chambers, waste chambers, conduits, vents, reagent chambers, reconstitution chambers and the like. The assay cartridges are used to conduct multiplexed nucleic acid measurements. Also described are kits including such cartridges, methods of using the same, and a reader configured to analyze an assay conducted using an assay cartridge.

Attenuated EHEC and clostridial toxins TcdA and TcdB based vaccine for Clostridium difficil associated disease (CDAD)

Provided are novel methods for expressing antigens in a vaccine vector strain, a live oral vaccine designed to prevent clostridium difficile-associated disease and methods for delivering antigens to the mucosal immune system of a subject.

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Electrochemiluminescence flow cell and flow cell components

An electrochemiluminescence cell comprising an electrode capable of inducing an electrochemiluminescence-active species to electrochemiluminesce. The electrode is preferably made of rhodium, iridium or an alloy of platinum, rhodium or iridium alloyed with an alloy material comprising a transition element. The electrode may be used as counter electrode and/or as a working electrode in the electrochemiluminescence cell. The cell preferably includes a counter electrode and a support attached to the counter electrode. The support comprises a transparent portion in optical registration with the working electrode. The counter electrode may include one or more field extending elements interposed between the transparent portion and the working electrode. The field extending element is preferably a ladder or a grid.

Assay apparatuses, methods and reagents

We describe apparatuses, systems, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of particulates in air and/or liquid samples derived therefrom in environmental monitoring.

Biodosimetry panels and methods

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

REDIRECTING TO A TRUSTED DEVICE FOR SECURED DATA TRANSMISSION

In various example embodiments, a machine is configured to redirect completion of a transaction to a trusted device. For example, the machine determines that a page involving the transaction is being displayed in a user interface of a first device. The page may be associated with the product or service. The machine identifies an interruption of the displaying of the page in the user interface of the first device. The machine identifies a second device that is trusted by the user. The machine transmits a communication including a notification to the second device. The notification indicates the transaction. 1. A system comprising: determine that a page involving a transaction is being displayed in a user interface of a first device, and', 'detect an interruption of the display of the page in the user interface of the first device,, 'a status module, comprising one or more hardware processors, configured toa device identifying module configured to identify a second device that is trusted by the user; anda communication module configured to transmit a communication including a notification to the second device, the notification indicating the transaction.2. The system of claim 1 , wherein the page involving the transaction is a payment page for a purchase of a product or service.3. The system of claim 1 , wherein:the communication is a first communication;the communication module is further configured to receive a second communication from the first device, the second communication including login data that identifies the user and device data that identifies the first device; and 'a mapping module configured to associate the first device with the user based on the login data and the device data.', 'the system further comprising4. The system of claim 1 , wherein:the communication is a first communication; transmit a second communication to the first device, the second communication including a request for the user to identify one or more other devices for receiving ...

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Diagnostic test

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.

Reagent storage in an assay device

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device.

Assay cartridges and methods of using the same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge.

Assay cartridge valve system

Assay cartridges are described that have a plurality of chambers and a fluidic network that includes fluidic conduits and a multi-port valve designed to selectively connect the valve inlet and one valve outlet through a fluidic connector in the valve as the remaining valve outlets are sealed.

METHODS FOR CONDUCTING MULTIPLEXED ASSAYS

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions. 2. The method of claim 1 , wherein the sample contains one or more additional analytes of interest and for each additional analyte of interest claim 1 , the combining step (a) further comprisescombining, in one or more steps, (ix) an additional targeting agent immobilized on an additional binding domain, an additional targeting agent complement connected to a linking agent, and an additional binding reagent connected to a supplemental linking agent, and (x) an additional binding complex on the additional binding domain comprising the additional targeting agent, the additional targeting agent complement, the additional binding reagent and the additional analyte;the forming step (b) further comprises forming (iii) an additional binding complex on the additional binding domain comprising the additional targeting agent, the additional targeting agent complement, the additional binding reagent and the additional analyte; andthe measurement in step (c) further comprises measuring the amount of the additional analyte on the additional binding domain.3. The method of claim 1 , whereinthe first targeting agent complement and the first binding reagent are provided as a pre-bound first targeting complex comprising the first targeting agent complement and the first binding reagent linked through a binding interaction between the linking agent and supplemental linking agent; andthe second targeting agent complement and the second binding reagent are provided as a pre-bound second targeting complex comprising the second targeting agent complement and the second binding reagent linked through a binding interaction between the linking agent and supplemental linking agent.4. The method of claim 3 , whereinthe first targeting complex is provided pre-bound to the ...

ASSAY CARTRIDGES AND METHODS OF USING THE SAME

Assay cartridges are described that have purification, reaction, and detection zones and other fluidic components which can include sample chambers, waste chambers, conduits, vents, reagent chambers, reconstitution chambers and the like. The assay cartridges are used to conduct multiplexed nucleic acid measurements. Also described are kits including such cartridges, methods of using the same, and a reader configured to analyze an assay conducted using an assay cartridge. 165.-. (canceled)66. A method of conducting an analysis of a sample in an assay cartridge , said cartridge comprising a fluidic network and a plurality of chambers , wherein said fluidic network comprises:a primary flow path and one or more fluidic conduits each intersecting said primary flow path and fluidically connecting said primary flow path to said chamber, wherein said fluidic network is configured to meter a volume of fluid in said network,said method comprising the steps of:(i) metering a volume of sample from said chamber to a second chamber;(ii) metering a volume of lysis buffer from said second chamber to said chamber;(iii) lysing said volume of sample;(iv) moving said lysate from said lysis chamber to a purification zone of said primary flow path;(v) extracting nucleic acid from said lysate;(vi) purifying said nucleic acid;(vii) moving said purified nucleic acid to a PCR reaction zone of said primary flow path;(viii) contacting said purified nucleic acid mixture with one or more PCR reagents;(ix) shuttling said mixture formed in step (viii) between first and second temperature controlled zones;(x) moving said mixture formed in step (ix) to said detection zone; and(xi) measuring a signal from said detection zone.67. The method of claim 66 , further comprising the steps of claim 66 , after step (ix) claim 66 , repeating steps (viii) and (ix) to form an amplified product mixture; and contacting said amplified product mixture with a detection reagent.68. The method of claim 66 , wherein the ...

Assay information management methods and devices

The present invention relates to methods, devices and systems for associating assay information with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system includes a reader adapted to read/erase/write information from/to an assay consumable identifier associated with the assay consumable. Various types of assay information are described, as well as methods of using such information in the conduct of an assay by an assay system.

BIODOSIMETRY PANELS AND METHODS

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure. 115.-. (canceled)16. A method assessing an absorbed dose of ionizing radiation or radiation-induced tissue injury in a human patient , said method comprising: wherein the multiplexed assay kit comprises an assay chamber and assay reagents for measuring the levels of the plurality of biomarkers in said sample, wherein said assay chamber includes said assay reagents arranged in an array and is configured to conduct a multiplexed assay measurement for said levels,', 'wherein the plurality of biomarkers comprises at least three biomarkers selected from the group consisting of:', '(a) a tissue-damage biomarker selected from salivary alpha-amylase, citrullinated proteins, S100B, SP-D, BPI, TSP, CA15-3, CKBB, CKMB, CKMM, FABP2, GFAP, and NSE;', '(b) a tissue-damage repair biomarker selected from Flt-3L, G-CSF, KFG, EPO, TPO, GM-CSF, and SDF-1a; and', '(c) a hematology-surrogate marker selected from CD5, CD-16b, CD20, CD177, CD26, CD27, CD40, and CD45;, 'measuring the level of a plurality of biomarkers in a sample from the patient with a multiplexed assay kit,'}comparing said level of said plurality of biomarkers in said sample to a level of said plurality of biomarkers in a control sample; anddistinguishing whether the patient received a dose of 0 Grays (Gy) from ≥2 Gy at 100% sensitivity and 100% specificity or the sample received a dose of ≤1 Gy from ≥2 Gy at 96.9% sensitivity and 98.5% specificity.17. The method of claim 16 , wherein said plurality of biomarkers comprises at least four of biomarkers (a)-(c).18. The method of claim 16 , wherein the kit further comprises ...

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 125.-. (canceled)26. A multiplexed assay kit used to evaluate the efficacy of a treatment regimen in a patient diagnosed with lung cancer , wherein the multiplexed assay kit is configured to measure a level of a plurality of biomarkers in a patient sample , wherein said kit comprises at least four different capture antibodies each bound to a solid surface , wherein each of said capture antibodies binds to a different human analyte selected from the group consisting of MDC , NME-2 , KGF , PIGF , Flt-3L , HGF , MCP1 , SAT-1 , MIP-1-b , GCLM , OPG , TNF RII , VEGF-D , ITAC , MMP-10 , GPI , PPP2R4 , AKR1B1 , Amy1A , MIP-1b , P-Cadherin and EPO.27. The kit of wherein said kit is further configured to compare said level to a level of a normal control.28. The kit of wherein each of said capture antibodies is bound to a discrete binding domain on said surface.29. The kit of wherein said cartridge comprises a flow cell having an inlet claim 42 , an outlet and a detection chamber.30. The kit of wherein said kit further comprises one or more additional assay reagents used in said assay claim 26 , said one or more additional assay reagents provided in one or more vials claim 26 , containers claim 26 , or compartments of said kit.31. A kit for the analysis of a lung cancer panel comprising(a) a multi-well assay plate comprising a plurality of wells, each well comprising at least four discrete binding domains to which at least four different capture antibodies are bound, wherein each of said capture antibodies binds to a different human analyte selected from the group consisting of: MDC, NME-2, KGF, PIGF, Flt-3L, HGF, MCP1, SAT-1, ...

Method, system, and computer-readable storage medium for heterogeneous data stream processing for a smart cart

A network service or application can receive dietary goals or conditions for a user or group of users. The network can determine threshold dietary amounts that users can receive over a predetermined time period to satisfy the goals or conditions. The network can monitor user consumption over the predetermined time period by collecting data from heterogeneous data streams (e.g., data associated with different structures, data types, types of data store, sources, processing rates, etc.), processing the data, storing the data using a distributive processing framework, and exposing optimized views into the data to provide smart virtual shopping cart functionality. The network can evaluate user consumption and food items placed into a virtual shopping cart to determine whether purchasing the items satisfy the thresholds, and if not, issue warnings, provide recommendations for substitute food items, and/or take other appropriate actions.

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 153-. (canceled)54. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises MDC, NME-2, KGF, PlGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, Amy1A, MIP-1b, P-Cadherin, EPO, MMP-2, EGFR, MMP-3, ErbB2, cytokeratin-19, E-cadherin, IL-6, osteopontin, cKit, uPA, NSE, cMET, MDC, Flt-1, CEA, cytokeratin-8, KGF, S100A6, IL2-R, and combinations thereof, and a set of labeled detection antibodies specific for said human analytes;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.55. The method of wherein said measuring step comprises conducting a multiplexed assay measurement of a plurality of said biomarkers in said test sample claim 54 , wherein said multiplexed assay measurement is conducted using one reaction volume comprising said test sample.56. The method of wherein said measuring step(s) are conducted on a single sample.57. The method of wherein said measuring step(s) are conducted in a single assay chamber.58. The method of wherein said assay chamber is a single well of an assay plate.59. The method of wherein said assay chamber is a cartridge.60. The method of wherein said sample is selected from the group consisting of blood claim 54 , peripheral blood mononuclear cells (PBMC) claim 54 , ...

KIDNEY FUNCTION BIOMARKERS

The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

ASSAY INFORMATION MANAGEMENT METHODS AND DEVICES

The present invention relates to methods, devices and systems for associating assay information with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system includes a reader adapted to read/erase/write information from/to an assay consumable identifier associated with the assay consumable. Various types of assay information are described, as well as methods of using such information in the conduct of an assay by an assay system. 188.-. (canceled)89. An assay system configured to use an assay cartridge in the conduct of an assay , said assay system comprising a reader adapted to perform the following operations:(i) reading cartridge lot identification information from a first consumable identifier associated with an assay consumable;(ii) reading lot specific parameters from an additional consumable identifier; and(iii) using said lot identification information and said lot specific parameters to adjust one or more operations performed by said assay system before, during and/or after the conduct of an assay by said system.90. The assay system of claim 89 , wherein said lot specific parameters are selected from the group consisting of (i) a revision level that determines schema used to interpret assay results and/or assay information; (ii) cartridge type; (iii) year of cartridge manufacture; (iv) cartridge lot number; (v) expiration date of cartridge and/or reagents used in said assay; (vi) a cross-talk correction matrix to account for chemical cross-reactivity; (vi) threshold values for assays to be conducted in said cartridge; (vii) a range for internal positive control(s) used in said assay; (viii) a ranges for each assay to be conducted in said cartridge for a positive control sample; and (ix) a software checksum.91. The assay system of claim 89 , wherein said first consumable identifier comprises non-volatile memory.92. The assay system of claim 91 , wherein said non-volatile memory is ...

KIDNEY FUNCTION BIOMARKERS

The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

Redirecting to a trusted device for secured data transmission

In various example embodiments, a machine is configured to redirect completion of a transaction to a trusted device. For example, the machine determines that a page involving the transaction is being displayed in a user interface of a first device. The page may be associated with the product or service. The machine identifies an interruption of the displaying of the page in the user interface of the first device. The machine identifies a second device that is trusted by the user. The machine transmits a communication including a notification to the second device. The notification indicates the transaction.

DIAGNOSTIC METHODS FOR INFLAMMATORY DISORDERS

The present invention relates to methods of diagnosing an inflammatory disorder in a patient, as well as methods of monitoring the progression of an inflammatory disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

REDIRECTING TO A TRUSTED DEVICE FOR SECURED DATA TRANSMISSION

In various example embodiments, a machine is configured to redirect completion of a transaction to a trusted device. For example, the machine determines that a page involving the transaction is being displayed in a user interface of a first device. The page may be associated with the product or service. The machine identifies an interruption of the displaying of the page in the user interface of the first device. The machine identifies a second device that is trusted by the user. The machine transmits a communication including a notification to the second device. The notification indicates the transaction. 1. A computer-implemented method comprising:determining, by one or more processors, that payment for a product or service is not received using a first device via an online marketplace webpage, the first device associated with a user profile;identifying, by the one or more processors, a second device associated with the user profile based at least in part on the determining; andtransmitting, to the second device associated with the user profile, a notification message comprising a reminder to complete a payment transaction based at least in part on the identifying.2. The method of claim 1 , further comprising:transmitting, to the first device, a request for identification of one or more devices for receiving notifications;receiving, from the first device, an identifier of the second device in response to the request for the identification of the one or more devices; andassociating the identifier of the second device with the user profile, wherein transmitting the notification message is based at least in part on the associating.3. The method of claim 1 , further comprising:completing the payment transaction for the product or service with the second device in response to the reminder to complete the payment transaction.4. The method of claim 1 , further comprising:detecting an interruption of a display corresponding to the payment transaction for the product or ...

KIDNEY FUNCTION BIOMARKERS

The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with kidney disease , said method comprising(a) obtaining a test sample from a patient undergoing treatment for kidney disease or a causative condition thereof;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises TNF RI, CHGA, TNF RII, S100A4, FABP5, E-Cadherin, TIMP1 and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.2. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with kidney disease , said method comprising(a) ordering a test comprising a measurement of a level of a biomarker in a test sample obtained from a patient undergoing treatment for kidney disease or a causative condition thereof, wherein said biomarker comprises TNF RI, CHGA, TNF RII, S100A4, FABP5, E-Cadherin, TIMP1, and combinations thereof;(b) comparing said level to a normal control level of said biomarker; and(c) evaluating from said comparing step (b) whether said patient is responsive to said treatment regimen.3. A method of administering a treatment regimen to a patient in need thereof for treating kidney disease , comprising:(a) obtaining a test sample from a patient undergoing treatment for kidney disease or a causative condition thereof;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises TNF RI, CHGA, TNF RII, S100A4, FABP5, E-Cadherin, TIMP1, and combinations thereof;(c) comparing said ...

Redirecting to a trusted device for secured data transmission

In various example embodiments, a machine is configured to redirect completion of a transaction to a trusted device. For example, the machine determines that a page involving the transaction is being displayed in a user interface of a first device. The page may be associated with the product or service. The machine identifies an interruption of the displaying of the page in the user interface of the first device. The machine identifies a second device that is trusted by the user. The machine transmits a communication including a notification to the second device. The notification indicates the transaction.

Assay cartridges and methods of using the same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge.

Biodosimetry panels and methods

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

ASSAY INFORMATION MANAGEMENT METHODS AND DEVICES

The present invention relates to methods, devices and systems for associating assay information with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system includes a reader adapted to read/erase/write information from/to an assay consumable identifier associated with the assay consumable. Various types of assay information are described, as well as methods of using such information in the conduct of an assay by an assay system. 1. A method of using an assay consumable in an assay system , wherein said assay consumable comprises a consumable identifier and said assay system comprises a reader adapted to perform an operation selected from the group consisting of (i) read information from said consumable identifier; (ii) erase information from said consumable identifier; (iii) write information to said consumable identifier; and (iv) combinations thereof , said method comprising the steps of (a) reading information from said consumable identifier; (b)conducting an assay in said assay system using said assay consumable; (c) writing information resulting from said assay conducted in step (b) to said consumable identifier; and (d) tracking use of said assay consumable.2. A method of tracking use of an assay consumable comprising an assay consumable identifier and a plurality of test sites , said method comprising (a) reading test site usage information from said assay consumable identifier; (b) identifying , based on said test site usage information , an available test site on said consumable; (c) carrying out an assay using said available test site; and (d) writing updated test site usage information to said assay identifier.3. The method of wherein said information is selected from the group consisting of chain of custody information; assay results obtained on said assay consumable or one or more test site(s); identity of samples that have been and/or will be assayed in said assay consumable or a ...

METHODS FOR CONDUCTING MULTIPLEXED ASSAYS

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions. 178.-. (canceled)80. The method of claim 79 , wherein (i) the first targeting agent and first targeting agent complement and (ii) the second targeting agent and second targeting agent complement each comprise a complementary oligonucleotide pair.92. The method of claim 79 , wherein the measuring step (c) further comprises measuring the presence of the first and second detectable labels via optical absorbance claim 79 , fluorescence claim 79 , phosphorescence claim 79 , chemiluminescence claim 79 , electrochemiluminescence claim 79 , light scattering claim 79 , or magnetism.93. The method of claim 92 , wherein the first and second detectable label is an electrochemiluminescent label and the measuring step (c) further comprises measuring an electrochemiluminescent signal and correlating the signal with an amount of first and second analyte in the sample.94. The method of claim 79 , wherein the first and second binding domains are positioned on an electrode and the measuring step further comprises applying a voltage waveform to the electrode to generate electrochemiluminescence.95. The method of claim 79 , wherein each of the first and second binding domains is an element of an array of binding domains.96. The method of claim 95 , wherein the array is located within a well of a multi-well plate.97. The method of claim 79 , wherein each of the first and second binding domains are each positioned on a surface of one or more microparticles.98. The method of claim 97 , wherein the particles are coded to allow for identification of specific particles and discrimination between the first and second binding domains. The present application is a continuation of copending application Ser. No. 14/847,761, filed on Sep. 8, 2015, which claims the benefit of U ...

METHOD AND SYSTEM FOR OFFLINE PAYMENT DELEGATION USING PERSONALIZED MULTIMEDIA MECHANISM

A system, method, and computer program product for providing personalized coordinated shopping among multiple participants in a network marketplace. Social group interactions are extended to shopping, to enhance the scope and efficiency of commerce. A shopping group comprising selected members of a social group includes an authorized purchaser and a number of shoppers who are not authorized to make purchases. A non-authorized purchaser selects desired items and sends a purchase approval request to the authorized purchaser, including a personalized video message describing and supporting the request. The personalized video message is sent to the authorized purchaser by communication means selected according to determined current availability, including via review of a social calendar. The authorized purchaser may approve, decline, or request further information from the requester, upon reviewing the purchase request. The authorized purchaser may modify the requested transaction, including the item actually purchased, the seller, and its shipping data. 1. A method for personalized shopping coordination , comprising:defining a shopping group comprising at least two users of a network marketplace system who are members of a social group, wherein a first user is authorized to make payments and a second user is not authorized to make payments;selecting, by the second user, an item to purchase;sending, by the second user, a personalized video message to the first user requesting payment authorization for the item; andproviding, by the first user, a payment authorization decision for the item.2. The method of claim 1 , wherein the first user adds the second user to the shopping group.3. The method of wherein the first user is at least one of a parent claim 1 , a child claim 1 , a spouse claim 1 , a friend claim 1 , a colleague claim 1 , a supervisor claim 1 , and a contractor claim 1 , and the second user is at least one of a parent claim 1 , a child claim 1 , a spouse ...

BIODOSIMETRY PANELS AND METHODS

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure. 19.-. (canceled)10. A computer readable medium having stored thereon a computer program which , when executed by a computer system operably connected to an assay system configured to measure a level of a plurality of biomarkers in a patient sample , causes the computer system to perform a method of calculating radiation dose by a method comprising:(a) fitting said measured level to a response surface model as a function of radiation dose or time;(b) computing a cost function for combining said plurality of biomarkers; and(c) selecting a radiation dose that minimizes said cost function at a known time interval.11. The computer readable medium of wherein said method further comprises the step of (e) comparing said radiation dose to a threshold value above which is indicative of radiation exposure.12. The computer readable medium of wherein said computing step (b) further comprises applying a weighting function claim 10 , W(radiation dose claim 10 , time) claim 10 , wherein Wis the weighting function of biomarker i as a function of radiation dose or time.13. The computer readable medium of wherein said cost function represents the total error for said plurality of biomarkers as a function of radiation dose.16. The computer readable medium of claim 10 , wherein the plurality of biomarkers in the patient sample comprise three or more biomarkers selected from the group consisting of CD20 claim 10 , Flt-3L claim 10 , CD177 claim 10 , AMY claim 10 , IL-12 claim 10 , and TPO.17. The computer readable medium of claim 16 , wherein the method further comprises assessing said radiation ...

Reagent storage in an assay device

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device.

REAGENT STORAGE IN AN ASSAY DEVICE

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device. 1. An assay device comprising (i) a reagent linked to a first targeting agent; and', '(ii) a surface linked to a second targeting agent,, '(a) a storage zone comprising a surface-reagent complex confined to said storage zone, said surface-reagent complex comprising'}wherein said reagent and said surface are linked, in said surface-reagent complex, via a releasable binding interaction between said first and second targeting agents; and(b) one or more use zones each configured to use said reagent in an assay for an analyte of interest in a sample.2. The assay device of wherein said one or more use zones each comprise an additional reagent used in said assay.3. The assay device of wherein said reagent is a binding reagent that binds a component of said assay conducted in said use zone.4. The assay device of wherein said binding reagent binds said analyte.5. The assay device of wherein said additional reagent binds said analyte.6. The assay device of wherein said binding reagent binds a complex formed between said additional reagent and said analyte.7. The assay device of wherein said one or more use zones each comprise a solid support and said additional reagent is bound to said solid support.8. The assay device of wherein said reagent comprises a detectable label.9. The assay device of wherein said detectable label is an ECL label.10. The assay device of wherein said storage zone and said one or more use zones are in fluidic communication along a fluid path.11. The assay device of wherein said one or more use zones each comprise two or more assay regions each configured to use said reagent in one or more assays conducted with said sample in said assay device.12. The assay device of wherein a first ...

Assay Cartridges and Methods of Using the Same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge. 1120-. (canceled)121. A method of collecting a liquid in an assay cartridge , said method comprises the steps of:(i) introducing liquid containing bubbles into a collection chamber via a collection conduit until a liquid level reaches a first height in said collection chamber, wherein said collection conduit is connected proximate to a top of said collection chamber;(ii) introducing additional liquid into said collection chamber via said collection conduit such that said additional liquid is transferred through a sensing conduit into a sensing chamber;(iii) detecting liquid in said sensing chamber; and(iv) transferring liquid substantially free of bubbles from said collection chamber through an outlet conduit, wherein said outlet conduit is connected proximate to a bottom of said collection chamberwherein the first height is less than a second height from the top to the bottom of said collection chamber.122. The method of wherein said collection chamber further comprises a baffle positioned adjacent to said collection conduit claim 121 , and said method further comprises contacting said liquid with said baffle and a wall of said collection chamber to constrain bubbles within said liquid.123. The method of wherein in the detecting step (iii) the liquid is detected by an optical sensor.124. The method of claim 123 , wherein the optical sensor is located on a cartridge reader.125. The method of claim 123 , wherein the optical sensor is located on the ...

Assay cartridge valve system

Assay cartridges are described that have a plurality of chambers and a fluidic network that includes fluidic conduits and a multi-port valve designed to selectively connect the valve inlet and one valve outlet through a fluidic connector in the valve as the remaining valve outlets are sealed.

SEARCH DETAIL DISPLAY USING SEARCH RESULT CONTEXT

The use of search context to determine a manner in which related items are to be display to a user upon selecting a search result of a number of search results generated by a search engine. Upon the user selecting one of the search result items, details regarding the selected search result item are then displayed. The details include a listing of related items that includes at least a set of strongly related items. The context of the plurality of search result items is used to determine a manner of display of the related items. Thus, the display manner for the related items may be different according to the context. 1. A method of a computing system presenting search results to a user , the method comprising:an act of the computing system detecting a user-selection of a search result item from amongst a plurality of search result items that were generated by a search engine; andan act of the computing system displaying details about the selected search result item in response to the user selecting the selected search result item, wherein the details includes at least a set of strongly related items,wherein a context of the plurality of search results is used to determine a manner to display for displaying the minimum set of related items.2. The method in accordance with claim 1 , wherein the context used to determine the manner of display is at least a portion of a search string of a user-initiated search request submitted to the search engine that resulted in the generation of the plurality of search result items.3. The method in accordance with claim 1 , wherein the context used to determine the manner of display is at least an identity of a web site in which was made a user-initiated search request that resulted in the plurality of search result items.4. The method in accordance with claim 1 , wherein the context used to determine the manner of display is at least a geographical location of a user that initiated a search request that resulted in the plurality of ...

BIODOSIMETRY PANELS AND METHODS

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure. 1. A multiplexed assay kit used to assess an absorbed dose of ionizing radiation or radiation-induced tissue injury in a patient sample , wherein said kit is configured to measure the level of a plurality of biomarkers in said sample and said plurality of biomarkers comprises:(a) a DNA-damage biomarker;(b) an inflammatory-response biomarker;(c) a tissue-damage biomarker;(d) a tissue-damage repair biomarker;(e) a hematology-surrogate marker; and(f) combinations thereof.2. The kit of wherein said plurality of biomarkers comprises at least two of biomarkers (a)-(e).3. The kit of wherein said plurality of biomarkers comprises at least four of biomarkers (a)-(e).4. The kit of wherein said plurality of biomarker is selected from the group consisting of:(a) a DNA-damage biomarker;(b) an inflammatory-response biomarker;(c) a tissue-damage biomarker;(d) a tissue-damage repair biomarker; and(e) a hematology-surrogate marker.5. The kit of further comprising instructions for correlating the level of said plurality of biomarkers present in the sample with the dose of radiation absorbed by the patient.6. The kit of further comprising a computer readable medium having stored thereon a computer program which claim 1 , when executed by a computer system claim 1 , causes the computer system to perform a method comprising correlating the level of said plurality of biomarkers present in the sample with the dose of radiation absorbed by the patient.7. A device capable of receiving the kit of or a component thereof to measure level of said plurality of biomarkers claim 1 , said device operatively ...

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

METHODS FOR CONDUCTING MULTIPLEXED ASSAYS

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Assay cartridges and method of using the same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge.

Assay Cartridges and Methods of Using the Same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge. 1. An assay cartridge comprising a sample chamber , a sample indicator window and an optical path from a reflecting surface to said indicator window , wherein said reflecting surface reflects a sample level in said sample chamber to said indicator window.2. The assay cartridge of wherein said sample indicator window comprises an indicating feature.3. The assay cartridge of wherein said indicating feature is an indicating line that indicates a fluid level within said sample chamber claim 2 , wherein said level is selected from the group consisting of a sample minimum claim 2 , a sample maximum claim 2 , a target level and a combination thereof.4. The assay cartridge of wherein said indicating feature is a boundary of said indicator window.5. The assay cartridge of wherein said reflecting surface is a mirrored surface.6. The assay cartridge of wherein said cartridge comprises a cartridge body and said reflecting surface is provided by total internal reflection at an angled surface in said cartridge body.7. The assay cartridge of wherein said angled surface is configured such that an angle of incidence along said optical path is greater than a critical angle for total internal reflection at said reflecting surface.8. The assay cartridge of wherein said angled surface is provided by a surface of a cavity within said cartridge body such that light traveling through said cartridge body along said optical path intersects an air-body interface at said ...

Assay Information Management Methods and Devices

The present invention relates to methods, devices and systems for associating assay information with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system includes a reader adapted to read/erase/write information from/to an assay consumable identifier associated with the assay consumable. Various types of assay information are described, as well as methods of using such information in the conduct of an assay by an assay system.

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

REAGENT STORAGE IN AN ASSAY DEVICE

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device. 1. An assay device comprising (i) a reagent linked to a first targeting agent; and', '(ii) a surface linked to a second targeting agent,, '(a) a storage zone comprising a surface-reagent complex confined to said storage zone, said surface-reagent complex comprising'}wherein said reagent and said surface are linked, in said surface-reagent complex, via a releasable binding interaction between said first and second targeting agents; and(b) one or more use zones each configured to use said reagent in an assay for an analyte of interest in a sample.2. The assay device of wherein said one or more use zones each comprise an additional reagent used in said assay.3. The assay device of wherein said reagent is a binding reagent that binds a component of said assay conducted in said use zone.4. The assay device of wherein said binding reagent binds said analyte.5. The assay device of wherein said additional reagent binds said analyte.6. The assay device of wherein said binding reagent binds a complex formed between said additional reagent and said analyte.7. The assay device of wherein said one or more use zones each comprise a solid support and said additional reagent is bound to said solid support.8. The assay device of wherein said reagent comprises a detectable label.9. The assay device of wherein said detectable label is an ECL label.10. The assay device of wherein said storage zone and said one or more use zones are in fluidic communication along a fluid path.11. The assay device of wherein said one or more use zones each comprise two or more assay regions each configured to use said reagent in one or more assays conducted with said sample in said assay device.12. The assay device of wherein a first ...

REAGENT STORAGE IN AN ASSAY DEVICE

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device. 1. A method of conducting an assay for an analyte of interest in a sample , wherein said method is conducted in an assay device comprising: (i) a reagent linked to a first targeting agent; and', '(ii) a surface linked to a second targeting agent,, '(a) a storage zone comprising a surface-reagent complex confined to said storage zone, said surface-reagent complex comprising'}wherein said reagent and said surface are linked, in said surface-reagent complex, via a releasable binding interaction between said first and second targeting agents; and(b) one or more use zones each configured to use said reagent in an assay for an analyte of interest in a sample;said method comprising:(x) introducing said sample to said one or more use zones;(y) subjecting said storage zone to a condition that releases said reagent from said surface-reagent complex;(z) transferring said reagent from said storage zone to said one or more use zones; and(xx) conducting said assay in said one or more use zones with said reagent.2. The method of wherein said condition is selected from increased or decreased temperature claim 1 , pH changes claim 1 , applying an electrical potential claim 1 , a change in ionic strength claim 1 , competition claim 1 , and combinations thereof.3. The method of wherein said condition comprises increasing the temperature of said storage zone.4. The method of wherein said increased temperature exceeds the melting temperature of said binding interaction.5. The method of wherein said reagent is a binding reagent that binds said analyte and said method further comprises detecting the amount of analyte bound to said binding reagent in said one or more use zones.6. The method of wherein said reagent comprises ...

METHODS FOR CONDUCTING MULTIPLEXED ASSAYS

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Reagent storage in an assay device

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device.

Assay cartridges and methods of using the same

Assay cartridges are described that have purification, reaction, and detection zones and other fluidic components which can include sample chambers, waste chambers, conduits, vents, reagent chambers, reconstitution chambers and the like. The assay cartridges are used to conduct multiplexed nucleic acid measurements. Also described are kits including such cartridges, methods of using the same, and a reader configured to analyze an assay conducted using an assay cartridge.

DIAGNOSTIC METHODS FOR INFLAMMATORY DISORDERS

The present invention relates to methods of diagnosing an inflammatory disorder in a patient, as well as methods of monitoring the progression of an inflammatory disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with Chronic Obstructive Pulmonary Disorder (COPD) , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises VEGF, ICAM-1, MCP-4, Thrombomodulin, P-selectin, bFGF, RANTES, and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.2. The method of wherein said measuring step comprises conducting a multiplexed assay measurement of a plurality of said biomarkers in said test sample claim 1 , wherein said multiplexed assay measurement is conducted using one reaction volume comprising said test sample.3. The method of wherein said method comprises measuring levels of two or more biomarkers.4. A method of further comprising one or more additional measuring steps including:(x) measuring a baseline level(s) of said biomarker before said treatment regimen is initiated, and said evaluating step further comprises comparing said level and said baseline level; and(y) measuring an interim level of said biomarker during said treatment regimen and said evaluating step further comprises comparing said level, said interim level and said baseline level.5. The method of claim 1 , wherein said evaluating step comprises comparing said level of said biomarker to a detection cut-off level claim 1 , wherein said level below said detection cut-off level is indicative of lung ...

Reagent Storage in an Assay Device

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device. 1. An assay device comprising (i) a reagent linked to a first targeting agent; and', '(ii) a surface linked to a second targeting agent,, '(a) a storage zone comprising a surface-reagent complex confined to said storage zone, said surface-reagent complex comprising'}wherein said reagent and said surface are linked, in said surface-reagent complex, via a releasable binding interaction between said first and second targeting agents; and(b) one or more use zones each configured to use said reagent in an assay for an analyte of interest in a sample.2. The assay device of wherein said one or more use zones each comprise an additional reagent used in said assay.3. The assay device of wherein said reagent is a binding reagent that binds a component of said assay conducted in said use zone.4. The assay device of wherein said binding reagent binds said analyte.5. The assay device of wherein said additional reagent binds said analyte.6. The assay device of wherein said binding reagent binds a complex formed between said additional reagent and said analyte.7. The assay device of wherein said one or more use zones each comprise a solid support and said additional reagent is bound to said solid support.8. The assay device of wherein said reagent comprises a detectable label.9. The assay device of wherein said detectable label is an ECL label.10. The assay device of wherein said storage zone and said one or more use zones are in fluidic communication along a fluid path.11. The assay device of wherein said one or more use zones each comprise two or more assay regions each configured to use said reagent in one or more assays conducted with said sample in said assay device.12. The assay device of wherein a first ...

DIAGNOSTIC METHODS FOR INFLAMMATORY DISORDERS

The present invention relates to methods of diagnosing an inflammatory disorder in a patient, as well as methods of monitoring the progression of an inflammatory disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with Chronic Obstructive Pulmonary Disorder (COPD) , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises VEGF, ICAM-1, MCP-4, Thrombomodulin, P-selectin, bFGF, RANTES, and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.27.-. (canceled)8. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with Rheumatoid Arthritis (RA) , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises TNF-RII, IL-6, TNF-R1, ICAM-1, TNF, and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.914.-. (canceled)15. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with Coronary Artery Disease (CAD) , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises RANTES;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient ...

Assay information management methods and devices

The present invention relates to methods, devices and systems for associating assay information with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system includes a reader adapted to read/erase/write information from/to an assay consumable identifier associated with the assay consumable. Various types of assay information are described, as well as methods of using such information in the conduct of an assay by an assay system.

ASSAY CARTRIDGES AND METHODS OF USING THE SAME

Assay cartridges are described that have purification, reaction, and detection zones and other fluidic components which can include sample chambers, waste chambers, conduits, vents, reagent chambers, reconstitution chambers and the like. The assay cartridges are used to conduct multiplexed nucleic acid measurements. Also described are kits including such cartridges, methods of using the same, and a reader configured to analyze an assay conducted using an assay cartridge.

Recombinant lectin variants

A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 orin an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4.

Redirecting to a trusted device for secured data transmission

In various example embodiments, a machine is configured to redirect completion of a transaction to a trusted device. For example, the machine determines that a page involving the transaction is being displayed in a user interface of a first device. The page may be associated with the product or service. The machine identifies an interruption of the displaying of the page in the user interface of the first device. The machine identifies a second device that is trusted by the user. The machine transmits a communication including a notification to the second device. The notification indicates the transaction.

HETEROGENEOUS DATA STREAM PROCESSING FOR A SMART CART

A network service or application can receive dietary goals or conditions for a user or group of users. The network can determine threshold dietary amounts that users can receive over a predetermined time period to satisfy the goals or conditions. The network can monitor user consumption over the predetermined time period by collecting data from heterogeneous data streams (e.g., data associated with different structures, data types, types of data store, sources, processing rates, etc.), processing the data, storing the data using a distributive processing framework, and exposing optimized views into the data to provide smart virtual shopping cart functionality. The network can evaluate user consumption and food items placed into a virtual shopping cart to determine whether purchasing the items satisfy the thresholds, and if not, issue warnings, provide recommendations for substitute food items, and/or take other appropriate actions. 1. A computer-implemented method , comprising:receiving, by a computing system, a dietary condition for a user account of the computing system;determining, using one or more processors of the computing system, a threshold dietary amount that can be consumed within a specified time period and satisfy the dietary condition;extracting first data from structured data associated with a first food item in a first data stream within the specified time period using a distributive processing framework of the computing system;extracting second data from unstructured data associated with the user account in a second data stream within the specified time period using the distributive processing framework;storing an association between the first data and the second data;determining a current dietary amount consumed by the user account within the time period based on the association between the first data and the second data;receiving a request from the user account within the time period to add a second food item to a virtual shopping cart;determining ...

Assay cartridges and methods of using the same

Assay cartridges are described that have purification, reaction, and detection zones and other fluidic components which can include sample chambers, waste chambers, conduits, vents, reagent chambers, reconstitution chambers and the like. The assay cartridges are used to conduct multiplexed nucleic acid measurements. Also described are kits including such cartridges, methods of using the same, and a reader configured to analyze an assay conducted using an assay cartridge.

DYNAMIC GROUP PURCHASE FLOWS USING AUTHORIZED TEMPORAL PAYMENT TOKENS

Systems, methods and media are provided for operating a group purchase event in a networked system. An example method comprises initiating a digital instance of a group purchase event and defining a target balance, identifying a potential contributor list from a social or community group, transmitting an electronic communication to first and second parties on the potential contributor list via an electronic communication pathway, and based on a received response to the electronic communication, authorizing the first and second parties to participate in the group purchase event. One example identifies and presents, in a display of an electronic device, a list of items purchasable at prices less than or equal to a current balance of a money pool, and monitors changes in the current balance. Based on a change in the current balance, the displayed list of items is dynamically updated. 1. A method for operating a group purchase event in a networked system , the method comprising:initiating a digital instance of a group purchase event and defining a target balance;identifying a potential contributor list from a social or community group;transmitting an electronic communication to first and second parties on the potential contributor list via an electronic communication pathway;based on a received response to the electronic communication, authorizing the first and second parties to participate in the group purchase event;prompting the first and second parties to make a financial contribution to the group purchase event in a defined amount based on the target balance;receiving respective financial contributions from the first and second parties in the defined or another amount;based on receipt of the financial contributions, issuing respective dynamic, time-based tokens representing an amount received from each party;storing the tokens in a database;aggregating the amounts received from the first and second parties to create a money pool and storing a current balance of the ...

BIODOSIMETRY PANELS AND METHODS

The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure. 1. A method of assaying peripheral blood leukocyte status in a sample comprising(a) measuring a level of a plurality of hematology surrogate biomarkers in a sample, said plurality of biomarkers comprises a lymphocyte cell surface marker, a neutrophil cell surface marker, and combinations thereof;(b) comparing said level of said biomarkers in said sample to a level of said biomarkers in a normal control sample; and(c) determining said peripheral blood leukocyte status based on said comparison step (b).2. The method of wherein said lymphocyte surface marker comprising CD5 claim 1 , CD20 claim 1 , CD26 claim 1 , CD27 claim 1 , CD40 claim 1 , and combinations thereof.3. The method of wherein said neutrophil cell surface marker comprising CD16b claim 1 , CD177 claim 1 , and combinations thereof.4. The method of wherein said sample is blood cell pellets claim 1 , serum or plasma.5. The method of wherein said sample is plasma.6. A method of assessing an absorbed dose of ionizing radiation in a plasma sample from a patient claim 1 , said method comprising(a) measuring the level of a hematology surrogate marker in said sample;(b) applying, by a processor, an algorithm to assess said absorbed dose in said patient based on said level of said hematology surrogate marker in said sample.7. The method of wherein said hematology-surrogate marker comprises CD5 claim 6 , CD-16b claim 6 , CD20 claim 6 , CD177 claim 6 , CD26 claim 6 , CD27 claim 6 , CD40 claim 6 , CD45 and combinations thereof.8. The method of wherein said algorithm quantifies an absorbed dose of ionizing radiation in the range ...

METHODS FOR CONDUCTING MULTIPLEXED ASSAYS

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions. 1. A method of conducting a multiplexed binding assay for a plurality of analytes of interest comprising (i) a sample comprising a first analyte of interest and a second analyte of interest,', '(ii) a first targeting agent immobilized on a first binding domain,', '(iii) a first targeting agent complement connected to a linking agent, wherein the first targeting agent complement is a binding partner of the first targeting agent,', '(iv) a first binding reagent connected to a supplemental linking agent, wherein the first binding reagent is a binding partner of the first analyte,', '(v) a second targeting agent immobilized on a second binding domain,', '(vi) a second targeting agent complement connected to a linking agent, wherein the second targeting agent complement is a binding partner of the second targeting agent,', '(vii) a second binding reagent connected to a supplemental linking agent, wherein the second binding reagent is a binding partner of the second analyte, and', '(viii) optionally, at least two copies of a bridging agent,, '(a) combining, in one or more steps, the following componentswherein,if the bridging agent is omitted, each linking agent is a binding partner of the supplemental linking agent, orif the bridging agent is included, the bridging agent has a first binding site for one of the linking agents and an additional binding site for one of the supplemental linking agents; (ii) a first binding complex on the first binding domain comprising the first targeting agent, the first targeting agent complement, the first binding reagent and the first analyte, and', '(iii) a second binding complex on the second binding domain comprising the second targeting agent, the second targeting agent complement, the second binding reagent and ...

Rate-limiting based on cardinality computation

A cloud-based service records time-series data of a plurality of metrics from a plurality of tenants. The time-series data comprises a series of measures of a metric at sequential points in time. The time-series data is recorded in database tables in a manner that consumes more resources when the cardinality of the time-series data is high. When the cardinality of the data for the tenant is too high, the tenant is blacklisted and further data for the tenant is not stored. In addition to identifying incoming time-series data by the tenant that produced it, the data may also identify its type. In this case, the cardinality of each type of data may be determined and the types of data may be individually allowed or blacklisted for the tenant.

Assay Cartridges and Methods of Using the Same

Assay cartridges are described that have purification, reaction, and detection zones and other fluidic components which can include sample chambers, waste chambers, conduits, vents, reagent chambers, reconstitution chambers and the like. The assay cartridges are used to conduct multiplexed nucleic acid measurements. Also described are kits including such cartridges, methods of using the same, and a reader configured to analyze an assay conducted using an assay cartridge. 1. An assay cartridge for conducting a PCR analysis of a sample , said cartridge comprising a chamber and a fluidic network including(a) a primary flow path comprising, from a proximate to a distal end, an inlet, a purification zone, a PCR reaction zone, and a detection zone, wherein said primary flow path further comprises one or more air vent ports, and(b) one or more fluidic conduits each intersecting said primary flow path and fluidically connected to said chamber, wherein said chamber is connected to an additional air vent port,and said PCR reaction zone comprises a first temperature controlled zone and a second temperature controlled zone and said fluidic network is configured to shuttle a metered volume of fluid between said first and second temperature controlled zones during a PCR reaction conducted in said PCR reaction zone.2. The assay cartridge of wherein said reaction zone further comprises a restriction zone positioned between said first and second reaction temperature controlled zones.3. The assay cartridge of claim 1 , wherein a fluidic conduit of said one or more fluidic conduits comprises a multi-conduit fluidic junction including (i) a first conduit connecting said primary flow path and said chamber claim 1 , and (ii) a second conduit connecting said chamber to said additional air vent port claim 1 , wherein said fluidic conduit is in communication with an optical fluid sensor at a position distal from said fluidic junction and said metered volume of fluid is defined by the ...

EX VIVO ANTIGEN AND ADJUVANT PULSED PERIPHERAL BLOOD MONONUCLEAR CELLS AS A SCREENING PLATFORM FOR CANDIDATE NOVEL VACCINES AND CANDIDATE ANTIGENS

Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs. 1. A system for providing a protective immune response in a subject , comprising a therapeutic amount of peripheral blood mononuclear cells that have been pulsed ex vivo with at least one antigen and an adjuvant , wherein the therapeutic amount of peripheral blood mononuclear cells does not include the vaccine and the adjuvant.2F. tularensis. The system of claim 1 , wherein the antigen is inactivated LVS.3S. pneumoniae. The system of claim 1 , wherein the antigen is an vaccine.4. The system of claim 1 , wherein the at least one antigen comprises a first antigen and a second antigen that is different than the first antigen.5F. tularensisS. pneumoniae. The system of claim 4 , wherein the first antigen is inactivated LVS (iFt) and the second antigen is an vaccine.6. The system of claim 1 , wherein the adjuvant is unsuitable for in vivo use in humans.7. A method of screening a vaccine and adjuvant combination claim 1 , comprising the steps of:providing a quantity of peripheral blood mononuclear cells;pulsing the quantity of peripheral blood mononuclear cells ex vivo with a vaccine and an adjuvant; andwashing the quantity of peripheral blood mononuclear cells to remove the vaccine and the adjuvant from the quantity of peripheral blood mononuclear cells;determining the immunogenicity of at least a portion of the quantity of ...

Assay modules having assay reagents and methods of making and using same

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

Assay cartridge valve system

Assay cartridges are described that have a plurality of chambers and a fluidic network that includes fluidic conduits and a multi-port valve designed to selectively connect the valve inlet and one valve outlet through a fluidic connector in the valve as the remaining valve outlets are sealed.

Lung cancer biomarkers

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.

METHODS AND APPARATUSES FOR DETERMINING THICKNESS OF A CONDUCTIVE LAYER

Methods and apparatuses for calibrating eddy current sensors. A calibration curve is formed relating thickness of a conductive layer in a magnetic field to a value measured by the eddy current sensors or a value derived from such measurement, such as argument of impedance. The calibration curve may be an analytic function having infinite number terms, such as trigonometric, hyperbolic, and logarithmic, or a continuous plurality of functions, such as lines. High accuracy allows the omission of optical sensors, and use of eddy current sensors for endpoint detection, transition call detection, and closed loop control in which a process parameter is changed based on the measured magnetic flux density change in one or more processing zones. 1. A method of processing a wafer , the method comprising:changing the thickness of a conductive layer on the wafer; andduring changing, monitoring the thickness of the conductive layer, wherein monitoring the thickness comprises correlating a measurement from an eddy current sensor to a thickness of the conductive layer, wherein correlating the measurement to the thickness comprises applying a model that includes either (1) a plurality of functions between measurement points of known thicknesses or (2) an analytic function having infinite order terms.2. The method of claim 1 , wherein changing comprises polishing the conductive layer.3. The method of claim 1 , wherein changing comprises plating the conductive layer.4. The method of claim 1 , wherein the measurement comprises a magnetic flux density change in a magnetic field.5. The method of claim 4 , wherein correlating the measurement to the thickness comprises calculating an argument of impedance.6. The method of claim 1 , wherein applying the model is accurate to within 5% error over a range from about 1 kÅ to about 20 kÅ.7. The method of claim 1 , wherein the analytic function comprises hyperbolic sine (sin h).8. The method of claim 1 , further comprising:indicating a transition ...

ASSAY APPARATUSES, METHODS AND REAGENTS

We describe apparatuses, systems, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of particulates in air and/or liquid samples derived therefrom in environmental monitoring. 1. An environmental monitoring system comprising a sample collection module fluidically connected to a biological agent detection module , wherein said detection module comprises(i) an integrated pipettor;(ii) a fluidic manifold for receiving and transferring sample to a well of a multi-well assay plate in said system;(iii) a light detection subsystem for measuring luminescence;(iv) a liquid handling subsystem; and(v) a plate handling subsystem.2. The environmental monitoring system of claim 1 , wherein said sample collection module processes air samples.3. The environmental monitoring system of claim 1 , wherein said sample collection module processes fluid samples.4. The environmental monitoring system of claim 2 , wherein said sample collection module is selected from the group consisting of filter-based collectors claim 2 , impactors claim 2 , wetted cyclones claim 2 , and combinations thereof.5. The environmental monitoring system of claim 4 , wherein said sample collection module further comprises a component selected from the group consisting of a sonicator claim 4 , a vortex mixer claim 4 , a shaker claim 4 , a simple mixer claim 4 , and combinations thereof.6. The environmental monitoring system of claim 3 , wherein said sample collection module concentrates biological agents suspended in a fluid sample by a method selected from the group consisting of filtration claim 3 , back-filtration claim 3 , affinity separation claim 3 , centrifugation claim 3 , and combinations thereof.7. The environmental monitoring system of further comprising a sample processing ...

ASSAY MODULES HAVING ASSAY REAGENTS AND METHODS OF MAKING AND USING SAME

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state. 1. A multi-well assay plate comprising a plate body with a plurality of wells defined therein , wherein said plurality of wells comprises:(a) a binding surface having a capture reagent immobilized thereon and(b) a reconstitutable dry reagent, wherein said dry reagent is free standing.2. The multi-well assay plate of claim 1 , wherein said reconstitutable dry reagent comprises a labeled detection reagent.3. The multi-well assay plate of claim 2 , wherein said reconstitutable dry reagent is a free-standing pill.4. The multi-well assay plate of claim 2 , wherein said binding surface is coated with a reconstitutable protective layer.5. The multi-well assay plate of further comprising a reconstitutable dry assay control analyte claim 2 , wherein said assay control analyte has binding affinity for said immobilized capture reagent and/or said labeled detection reagent.6. The multi-well assay plate of claim 5 , wherein said assay control analyte has binding affinity for claim 5 , but is not bound to claim 5 , said immobilized capture reagent and/or said labeled detection reagent.7. The multi-well assay plate of further comprising one or more additional immobilized capture reagents claim 2 , wherein said capture reagent and additional capture reagents form a patterned array of binding domains on ...

DIAGNOSTIC TEST

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention. 1. A method for treating an inflammatory bowel disease in a human comprising the steps of:a) obtaining a sample from a patient suspected of having an inflammatory bowel disease and performing an assay to measure a level of soluble TNF receptor II (sTNFRII) in said sample;b) performing an assay to measure in said sample or another sample obtained from said patient a level of an additional analyte, wherein said additional analyte is MIP-1(3; andc) administering a suitable drug to said human if said sTNFRII level is above a predetermined level and said additional analyte level is below a predetermined level.2. The method of claim 1 , wherein said administering step comprises comparing said sTNFRII level and said additional analyte level to an analyte profile indicative of inflammatory bowel disease.3. The method of claim 1 , wherein said administering step further comprises distinguishing ulcerative colitis from Crohn's disease on the basis of said sTNFRII level and said additional analyte level.4. The method of claim 3 , wherein said distinguishing ulcerative colitis from Crohn's disease comprises comparing said analyte level and said additional analyte level to profiles ...

ENCRYPTION IN A WIRELESS TELECOMMUNICATIONS

An example of the present invention is a method of transmitting encrypted user data to a mobile terminal in a wireless telecommunications network. The method comprises sending to the mobile terminal a data packet. The data packet comprises both an identifier of encryption information to used in recovering encrypted user data, and user data encrypted using said encryption information. 1. A method of transmitting encrypted user data to a mobile terminal in a wireless telecommunications network , the method comprising:sending to the mobile terminal a data packet, the data packet comprising both:an identifier of encryption information for use by the mobile terminal in initializing a security context that enables the mobile terminal to recover encrypted user data in response to receipt of the data packet, anduser data encrypted using said encryption information;wherein the network comprises an LTE network.2. A method according to claim 1 , wherein the identifier of the encryption information comprises an identifier of an encryption algorithm.3. A method according to claim 2 , wherein the encryption information comprises an encryption key.4. A method according to claim 2 , wherein the user data comprises user traffic data.5. A method according to claim 2 , further comprising the step of the mobile terminal using the identified encryption information to recover the user data.6. A method according to claim 5 , further comprising the mobile terminal storing the identified encryption information for use in recovering encrypted user data in a subsequently received data packet.7. A method according to claim 1 , wherein the user data comprises user signaling data.8. A method according to claim 7 , wherein the user signaling data comprises an NAS message or an RRC message.9. A method according to claim 1 , further comprising the step of the mobile terminal using the identified encryption information to recover the user data.10. A method according to claim 9 , further comprising ...

MULTIPLEXED ASSAY KIT TO EVALUATE THE EFFICACY OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention. 118.-. (canceled)19. A method for evaluation of the effectiveness of a drug and/or drug candidate in treating an inflammatory bowel disease (IBD) comprising the steps of:(a) performing an assay with a multi-well assay plate of a sample obtained from a human, the multi-well assay plate comprising a plurality of wells, each well comprising at least four discrete binding domains with capture antibodies to which a plurality of biomarkers are bound, said plurality of biomarkers are selected from the group consisting of soluble Tumor Necrosis Factor receptor II (sTNFRII) and Macrophage Inflammatory Protein-1beta (MIP-1 beta), and at least two additional biomarkers selected from the group consisting of eotaxin, Soluble Interleukin-6 Receptor (sIL-6R), Monocyte Chemoattractant Protein 1 (MCP-1), Regulated on Activation, Normal T cell Expressed and Secreted protein (RANTES), said multi-well plate further comprising in one or more vials, containers, or compartments, a set of labeled detection antibodies specific for said plurality of biomarkers;(b) determining a first ratio of sTNFRII to MIP-1beta in a the sample;(c) determining a second ratio of sTNFRII to MIP-1beta in a group ...

OFFLINE ACTIVATION FOR APPLICATION(S) INSTALLED ON A COMPUTING DEVICE

Embodiments described herein enable a device to be activated/re-activated offline using device-bound activation/licensing information stored in that device's firmware. By storing the necessary licensing data in the device's firmware, the loss of data when the operating system software is reinstalled is avoided. The foregoing may be accomplished by “binding” data into the licensing data. This is done in order to make the license unusable on a different device, even on the exact same model of the device. Right-of-use information indicating which software components, versions, editions, configurations, etc. are licensed for use may also be included. The licensing data may also be provisioned to the device's firmware during device manufacturing to avoid the need for the user to contact the licensor company when the device reaches the end user. The process of issuing the device-bound license can also be delegated to another party by means of an issuance license. 1. A computing device , comprising:at least one processor circuit; andat least one memory that stores program code configured to be executed by the at least one processor circuit, the program code comprising:a device management agent configured to:transmit a request for licensing data for a software application installed on the computing device to an activation server maintained by a manufacturer of the computing device;receive the licensing data from the activation server; andstore the licensing data in firmware of the computing device, the licensing data including binding data that binds the licensing data to the computing device and grant information that specifies one or more attributes of the software application that are authorized for use on the computing device, the licensing data enabling offline activation of the software application.2. The computing device of claim 1 , the device management agent further configured to:generate an identifier that identifies the computing device, the identifier being ...

Assay Apparatuses, Methods and Reagents

We describe apparatuses, systems, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of particulates in air and/or liquid samples derived therefrom in environmental monitoring.

PROTEIN FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 1. 1. A lectin protein for use in the treatment or prevention of inflammation in a subject in need thereof.2. The lectin protein for use as claimed in claim 1 , wherein the lectin protein comprises an amino acid sequence having at least 60% homology to SEQ ID NO. 1.3. The lectin protein for use as claim in or claim 1 , wherein the lectin protein comprises an amino acid sequence having at least 60% homology to SEQ ID NO: 2 claim 1 , 3 claim 1 , or 4.4. The lectin protein for use as claimed in claim 2 , wherein the lectin protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO. 2 claim 2 , SEQ ID NO. 3 or SEQ ID NO. 4.5. The lectin protein for use as claimed in any preceding claim claim 2 , wherein the lectin protein is recombinant.6. The lectin protein for use as claimed in any one of to claim 2 , wherein the amino acid sequence has at least 70% claim 2 , 80% claim 2 , 90% claim 2 , 95% claim 2 , 96% claim 2 , 97% claim 2 , 98% or 99% homology to SEQ ID NO. 1.7. The lectin protein for use as claimed in any preceding claim claim 2 , wherein the lectin protein is capable of inhibiting the secretion of inflammatory cytokines.8. The lectin protein for use as claimed in any preceding claim claim 2 , wherein the lectin protein is capable of reducing C-reactive protein (CRP) levels in blood.9. The lectin protein for use as claimed in any preceding claim claim 2 , wherein the lectin protein is capable of stimulating ACP activity and/or collagen levels.10. The lectin protein for use as claimed in any preceding claim claim 2 , wherein the subject has a chronic inflammatory disease.11. The lectin protein for use ...

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises MDC, NME-2, KGF, PIGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, AmylA, MIP-1b, P-Cadherin, EPO, MMP-2, EGFR, MMP-3, ErbB2, cytokeratin-19, E-cadherin, IL-6, osteopontin, cKit, uPA, NSE, cMET, MDC, Flt-1, CEA, cytokeratin-8, KGF, S100A6, IL2-R, and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.2. The method of wherein said measuring step comprises conducting a multiplexed assay measurement of a plurality of said biomarkers in said test sample claim 1 , wherein said multiplexed assay measurement is conducted using one reaction volume comprising said test sample.3. The method of wherein said measuring step(s) are conducted on a single sample.4. The method of wherein said measuring step(s) are conducted in a single assay chamber.5. The method of wherein said assay chamber is a single well of an assay plate.6. The method of wherein said assay chamber is a cartridge.7. The method of wherein said sample is selected from the group consisting of blood claim 1 , peripheral blood mononuclear cells (PBMC) claim 1 , isolated blood cells claim 1 , urine claim 1 , serum and plasma.8. The method of wherein said sample is ...

CELLULAR WIRELESS NETWORK AND METHOD OF OPERATION

A method of operating a cellular wireless network comprises broadcasting information about Internet Multimedia Subsystem (IMS) emergency call capability of the network on a broadcast channel in a cell of the network. This information may in one method concern the IMS emergency call capability of a base station included in the network and in another method it may include IMS emergency call capability of a base station and the core network. 15-. (canceled)6. A method of operating a cellular wireless network , comprising:broadcasting information about a capability of a cellular wireless network on a broadcast channel in a cell of the cellular wireless network from an access node associated with the cell, wherein the information about the capability includes information about a combined packet switched emergency call capability of a packet core of the cellular wireless network and the access node;allowing a user equipment to perform emergency calls in the cell where the information broadcast about the capability indicates packet switched emergency calls are supported; andmaking the user equipment select a different cell which supports emergency calls where the information broadcast about the capability indicates packet switched emergency calls are not supported;wherein the user equipment selects the different cell that supports emergency calls after receiving the broadcast with the information about the capability indicating packet switched emergency calls are not supported.7. The method of wherein the broadcast information includes information about at least one of local regulation and operator's policy regarding packet switched emergency calls.8. The method of wherein the combined packet switched emergency call capability is an Internet Protocol Multimedia Subsystem (IMS) emergency call capability.9. The method of wherein the broadcast information includes an Internet Protocol Multimedia Subsystem (IMS) emergency call capability of the access node;wherein the access ...

ASSAY CARTRIDGE VALVE SYSTEM

Assay cartridges are described that have a plurality of chambers and a fluidic network that includes fluidic conduits and a multi-port valve designed to selectively connect the valve inlet and one valve outlet through a fluidic connector in the valve as the remaining valve outlets are sealed. 146-. (canceled)47. A method of moving fluid in an assay cartridge comprising a plurality of chambers and a fluidic network including a plurality of fluidic conduits connecting said plurality of chambers and a multi-port valve having:a cap;a stator comprising a rotor engagement member, a valve inlet, and a plurality of valve outlets accessible to one or more fluidic conduits in said fluidic network; anda rotor biased toward said stator and comprising a sealing member disposed between said rotor and said stator, a spring, an instrument interface element, and a stator engagement member configured to disengage said rotor when said stator engagement member is in communication with said rotor engagement member, introducing a fluid slug into said fluidic network;', 'applying, selectively, pressure or vacuum at one or more fluidic junctions in said fluidic network to move said fluid slug through said fluidic network; and', 'directing movement of said fluid slug through said fluidic network by engaging said multi-port valve to fluidically connect said valve inlet to one of said valve outlets through a fluidic connector on the rotor while said sealing member seals the remaining valve outlets., 'said method comprising the steps of This invention was made with federal support under Contract No. W81WH-10-2-0155 awarded under the U.S. Army Medical Research Acquisition Act. The U.S. government has certain rights in the invention.Reference is made to copending application Ser. No. 13/343,834, filed Jan. 5, 2012 and Ser. No. 12/959,952, filed Dec. 3, 2010. The disclosures of each of these applications are incorporated herein by reference.This application relates to apparatuses incorporating ...

PARENTERAL UNIT DOSAGE FORM OF DIHYDROERGOTAMINE

A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months. 2. The parenteral unit dosage form according to claim 1 , wherein the pH of the aqueous solution is in the range of 4.2 and 4.8.3. The parenteral dosage form according to claim 1 , wherein the aqueous solution is free of preservative or complexing agent.4. The parenteral unit dosage form according to claim 1 , wherein the pharmaceutical acceptable salt of dihydroergotamine is dihydroergotamine mesylate and it is present at a concentration ranging from 0.5 to 1.5 mg/ml.5. The parenteral unit dosage form according to claim 1 , further comprising and one or more co-solvents.6. An auto-injector or a prefilled syringe comprising the parenteral unit dosage form of .7. The auto-injector or a prefilled syringe according to claim 6 , wherein the dosage form is further covered with an overwrap pouch. This disclosure relates to migraine and cluster headache treatments. This disclosure specifically relates to a parenteral unit dosage form of dihydroergotamine comprising an aqueous solution of dihydroergotamine or its pharmaceutically acceptable salt.Dihydroergotamine mesylate is the methanesulphonate salt of dehydrogenated ergot alkaloid. It is used for the acute treatment of migraine and cluster headache episodes. Dihydroergotamine is a serotonin receptor agonist and causes vasoconstriction of the intracranial blood vessels. Oral bioavailability of dihydroergotamine is poor and it is not available in oral form in the U.S. Dihydroergotamine is ...

LUNG CANCER BIOMARKERS

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein. 1. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer , said method comprising(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises MDC, NME-2, KGF, PIGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, Amy1A, MIP-1b, P-Cadherin, EPO, and combinations thereof;(c) comparing said level to a normal control level of said biomarker; and(d) evaluating from said comparing step (c) whether said patient is responsive to said treatment regimen.2. A method for evaluating the efficacy of a treatment regimen in a patient diagnosed with lung cancer , said method comprising(a) ordering a test comprising a measurement of a level of a biomarker in a test sample obtained from a patient undergoing said treatment regimen for lung cancer, wherein said biomarker comprises MDC, NME-2, KGF, PIGF, Flt-3L, HGF, MCP1, SAT-1, MIP-1-b, GCLM, OPG, TNF RII, VEGF-D, ITAC, MMP-10, GPI, PPP2R4, AKR1B1, Amy1A, MIP-1b, P-Cadherin, EPO, and combinations thereof;(b) comparing said level to a normal control level of said biomarker; and(c) evaluating from said comparing step (b) whether said patient is responsive to said treatment regimen.3. A method of administering a treatment regimen to a patient in need thereof for treating lung cancer , comprising:(a) obtaining a test sample from a patient undergoing said treatment regimen for lung cancer;(b) measuring a level of a biomarker in said test sample, wherein said biomarker comprises ...

ASSAY MODULES HAVING ASSAY REAGENTS AND METHODS OF MAKING AND USING SAME

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state. 131-. (canceled)32. A multi-well assay plate comprising a plate body with a plurality of wells defined therein comprising:(a) a plurality of detection wells, wherein each detection well comprises a binding surface having a capture reagent immobilized thereon and 'wherein at least one detection well and one reagent reconstitution well comprise matched capture and detection reagents for measuring an analyte of interest.', '(b) a plurality of reagent reconstitution wells, wherein each reagent reconstitution well comprises a reconstitutable labeled detection reagent,'}33. A multi-well assay plate comprising a plate body with a plurality of wells defined therein comprising: (i) have well floors and well walls, wherein said well walls have inner wall surfaces and outer wall surfaces,', '(ii) are arranged in a regular two dimensional pattern, and', '(iii) comprise, on an inner surfaces of each of said detection wells, a binding surface having a capture reagent immobilized thereon array; and, '(a) a plurality of detection wells, wherein said detection wells'} (i) have well floors and well walls, wherein said well walls are defined by outer wall surfaces of said detection wells and by rib elements connecting the outer wall surfaces of adjacent detection wells and', '(ii) comprise, in each reagent ...

Methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Delivery of Correction Packages

A system, a method, and a computer-program product for delivering of correction packages are disclosed. At least one correction instruction is generated based on at least one correction to a software application. At least one correction package is assembled and linked to the generated correction instruction. The assembled correction package is transported to the software application for applying to the software application. 1. A computer-implemented method , comprising:generating at least one correction instruction based on at least one correction to a software application;assembling at least one correction package, and linking the assembled at least one correction package to the generated at least one correction instruction; andtransporting the assembled correction package to the software application for applying to the software application;wherein the at least one of the generating, the assembling, and the transporting is performed by at least one processor of at least one computing system.2. The method according to claim 1 , wherein the correction package includes a plurality of corrections and corresponding correction instruction metadata.3. The method according to claim 2 , wherein at least one correction instruction is dependent on at least another correction instruction based on at least one dependency.4. The method according to claim 3 , wherein the at least one dependency includes at least one of the following: a correction instruction being dependent on another correction instruction claim 3 , a correction instruction being dependent on an external requirement of the software application claim 3 , and a correction being dependent on at least one required correction for the software application.5. The method according to claim 3 , wherein the at least one dependency is determined byidentifying a transport order included in at least one support package for the software application;identifying at least one correction request for the software application for ...

Assay Cartridge Valve System

Assay cartridges are described that have a plurality of chambers and a fluidic network that includes fluidic conduits and a multi-port valve designed to selectively connect the valve inlet and one valve outlet through a fluidic connector in the valve as the remaining valve outlets are sealed. 1. An assay cartridge comprising:a) a plurality of chambers; and i) a plurality of fluidic conduits connecting said plurality of chambers; and', (y) a stator comprising a rotor engagement member, a valve inlet, and a plurality of valve outlets accessible to one or more fluidic conduits in said fluidic network; and', '(z) a rotor biased toward said stator and comprising a sealing member disposed between said rotor and said stator, a spring, and a stator engagement member configured to disengage said rotor when said stator engagement member is in communication with said rotor engagement member,', 'wherein, when engaged, said rotor is rotated to fluidically connect said valve inlet to one of said valve outlets through a fluidic connector on the rotor while said sealing member seals the remaining valve outlets., 'ii) a multi-port valve comprising], 'b) a fluidic network including'}2. The assay cartridge of wherein said spring is disposed between said rotor and said cap.3. The assay cartridge of wherein said spring comprises a top surface claim 1 , a bottom surface claim 1 , a cylindrical body comprising a central vertical axis disposed between said top and bottom surfaces and a plurality of pairs of axially spaced radially extending grooves surrounding said central vertical axis claim 1 , and a plurality of through-holes intersecting said central vertical axis at a position perpendicular to the intersection of said plurality of pairs of grooves to said central vertical axis.4. The assay cartridge of wherein said plurality of pairs of grooves and said plurality of through-holes define a plurality of ribs in said cylindrical body.5. The assay cartridge of wherein said spring ...

Assay Cartridge Valve System

Assay cartridges are described that have a plurality of chambers and a fluidic network that includes fluidic conduits and a multi-port valve designed to selectively connect the valve inlet and one valve outlet through a fluidic connector in the valve as the remaining valve outlets are sealed. 139-. (canceled)40. A method of using a multi-port valve in an assay cartridge , wherein said cartridge comprises a plurality of chambers and a fluidic network including (i) a plurality of fluidic conduits connecting said plurality of chambers; and (ii) a multi-port valve comprising:(x) a cap;(y) a stator comprising a rotor engagement member, a valve inlet, and a plurality of valve outlets accessible to one or more fluidic conduits in said fluidic network; and said method comprising the steps of:', '(a) contacting said instrument interface element with an instrument stepper motor;', '(c) connecting, fluidically, said valve inlet to one of said valve outlets through a fluidic connector on the rotor; and', '(b) rotating said rotor to disengage said rotor and stator engagement members;'}], '(z) a rotor biased toward said stator and comprising a sealing member disposed between said rotor and said stator, a spring, an instrument interface element, and a stator engagement member configured to disengage said rotor when said stator engagement member is in communication with said rotor engagement member,'}(d) sealing the remaining valve outlets by contacting said sealing member to said stator.41. The method of wherein said integrated spring comprises a top surface claim 40 , a bottom surface claim 40 , a cylindrical body comprising a central vertical axis disposed between said top and bottom surfaces and a plurality of pairs of axially spaced radially extending grooves surrounding said central vertical axis claim 40 , and a plurality of through-holes intersecting said central vertical axis at a position perpendicular to the intersection of said plurality of pairs of grooves to said ...

ENCRYPTION IN A WIRELESS TELECOMMUNICATIONS

An example of the present invention is a method of transmitting encrypted user data to a mobile terminal in a wireless telecommunications network. The method comprises sending to the mobile terminal a data packet. The data packet comprises both an identifier of encryption information to be used in recovering encrypted user data, and user data encrypted using the encryption information. 1. A method in a wireless telecommunications network , the method comprising:a mobile terminal receiving a data packet, the data packet comprising both an identifier of encryption information to be used in recovering encrypted user data, and user data encrypted using the encryption information;in response to receipt of the data packet, the mobile terminal initializing its security context using the identified encryption information;the mobile terminal using the identified encryption information to recover the user data; andthe mobile terminal storing the identified encryption information for use in recovering encrypted user data in a subsequently received data packet until receiving another identifier of encryption information.2. The method of claim 1 , wherein the encryption information comprises an encryption algorithm.3. The method of claim 2 , wherein the user data comprises user signalling data.4. The method of claim 3 , wherein the user signalling data comprises an NAS message or RRC message.5. The method of claim 1 , wherein the encryption information comprises an encryption key.6. The method of claim 5 , wherein the user data comprises user signalling data.7. The method of claim 6 , wherein the user signalling data comprises an NAS message or RRC message.8. The method of claim 1 , wherein the user data comprises user signalling data.9. The method of claim 8 , wherein the user signalling data comprises an NAS message or RRC message.10. The method of claim 1 , wherein the user data comprises user traffic data.11. The method of claim 1 , wherein the data packet comprising a ...

METHODS FOR CONDUCTING MULTIPLEXED ASSAYS

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions. 1. A method of conducting a multiplexed binding assay for a plurality of analytes comprising a first analyte and a second analyte of interest comprising (i) a sample comprising the plurality of analytes comprising the first analyte of interest and the second analyte of interest,', '(ii) a first targeting agent immobilized on a first binding domain, wherein the first targeting agent comprises an oligonucleotide,', '(iii) a first targeting agent complement connected to a first linking agent, wherein the first targeting agent complement comprises an oligonucleotide complementary to the first targeting agent oligonucleotide, forming a first oligonucleotide pair,', '(iv) a first binding reagent connected to a first supplemental linking agent, wherein the first binding reagent is a binding partner of the first analyte,', '(v) a second targeting agent immobilized on a second binding domain, wherein the second targeting agent comprises an oligonucleotide,', '(vi) a second targeting agent complement connected to a second linking agent, wherein the second targeting agent complement comprises an oligonucleotide complementary to the second targeting agent oligonucleotide, forming a second oligonucleotide pair,', '(vii) a second binding reagent connected to a second supplemental linking agent, wherein the second binding reagent is a binding partner of the second analyte, and', '(viii) at least two copies of a bridging agent,, '(a) combining, in one or more steps, the following componentswherein,the first copy of the bridging agent has a first binding site for the first linking agent and an additional binding site for the first supplemental linking agent and a second copy of the bridging agent has a first binding site for the second linking agent and an ...

RESPONDING TO PAGING REQUESTS WHILE WAITING TO REQUEST A CONNECTION TO A WIRELESS NETWORK

A user equipment, radio control node, method and computer program are disclosed. The user equipment is configured to communicate with other devices across a wireless communication network comprising a plurality of radio coverage cells, the user equipment being configured to respond to receipt of a message from the network, the message comprising a wait time, to not transmit a connection request until after expiry of the wait time; wherein the user equipment is configured during the wait time to receive paging requests from the network; and is configured to respond to at least some of the paging requests, the user equipment being configured to select the at least some of the paging requests to respond to in dependence upon paging information received from the network. 1. A user equipment configured to communicate with other devices across a wireless communication network comprising a plurality of radio coverage cells , said user equipment being configured to respond to receipt of a message from said network , said message comprising a wait time , to not transmit a connection request until after expiry of said wait time; whereinsaid user equipment is configured during said wait time to receive paging requests from said network; and is configured to respond to at least some of said paging requests, said user equipment being configured to select said at least some of said paging requests to respond to in dependence upon paging information received from said network.2. A user equipment according to claim 1 , wherein said paging information comprises an indication of types of paging requests that must be responded to claim 1 , said user equipment being configured during said wait time to respond to said types of paging requests that must be responded to.3. A user equipment according to claim 1 , wherein said paging information is received as one of:a part of a system information broadcast;said message comprising said wait time; anda signal associated with said paging ...

ASSAY MODULES HAVING ASSAY REAGENTS AND METHODS OF MAKING USING SAME

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state. 141-. (canceled)42. A method of carrying out an assay in a multi-well assay plate , the multi-well assay plate comprising a plate body with a plurality of wells defined therein comprising: (a) a plurality of detection wells , wherein each detection well comprises a binding surface having a capture reagent immobilized thereon and (b) a plurality of reagent reconstitution wells , wherein each reagent reconstitution well comprises a reconstitutable labeled detection reagent , wherein at least one detection well and one reagent reconstitution well comprise matched capture and detection reagents for measuring an analyte of interest , the method comprising:(a) adding a sample to one of said reagent reconstitution wells,(b) reconstituting reconstitutable dry labeled detection reagents in said reconstitution well to form one or more reaction mixture(s),(c) transferring an aliquot of said reaction mixture to one or more detection wells,(d) incubating said reaction mixture in said detection well(s) under conditions that promote binding of said capture and detection reagents to their corresponding binding partners, and(e) measuring formation of complexes comprising said immobilized capture reagents and said labeled binding reagent.43. The method of claim 42 , wherein said multi-well assay plate can ...

Highly efficient enzymatic process to produce (r)-3-quinuclidinol

The present invention relates to enzymatic reduction of 3-quinuclidinone to (R)-3-quinuclidinol (Scheme I), by reacting 3-quinuclidinone with a variant of ketoreductase enzyme derived from Rhodotorula rubra . The invention also relates to enzymatically produced (R)-3-quinuclidinol wherein the substrate loading capacity of the enzyme is not less than 100 g/L.

DIAGNOSTIC TEST

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention. 1. A multiplexed assay kit used to evaluate the efficacy of a treatment regimen in a patient diagnosed with inflammatory bowel disease , said kit is configured to measure a level of a plurality of biomarkers in a patient sample , said plurality of biomarkers comprises soluble TNF receptor II (sTNFRII) and MIP-1beta , and at least one additional biomarker comprising eotaxin , sIL-6R , MCP-1 , RANTES , and combinations thereof.2. The kit of wherein said kit is further configured to compare said level to a level of a normal control.3. The kit of wherein said at least one additional biomarker comprises MCP-1.4. The kit of wherein said kit is configured to measure said level using an immunoassay.5. The kit of wherein said kit comprises a multi-well assay plate including a plurality of assay wells used in an assay conducted in said kit claim 1 , said plurality of assay wells configured to measure said level of said plurality of biomarkers and said at least one additional biomarker in said sample.6. The kit of wherein a well of said assay plate comprises a plurality of assay domains claim 5 , at least two of said assay domains comprising reagents for measuring different ...

ASSAY APPARATUSES, METHODS AND REAGENTS

We describe apparatuses, systems, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of particulates in air and/or liquid samples derived therefrom in environmental monitoring. 1. An apparatus for measuring signals from wells of sealed multi-well assay plates , the apparatus comprising:(a) a sealed multi-well assay plate;(b) a seal removal tool for removing seals from wells of said multi-well plates, wherein said seal removal tool comprises a piercing probe with a seal piercing tip and a through-hole parallel to said piercing direction and off-set from said piercing tip;(c) a piercing probe guide having an opening formed therein along which the piercing probe slides in the piercing direction;(d) a pipetting probe that is attached to the piercing probe guide and movably located in said through-hole such that it can be withdrawn into said piercing probe during seal removal operations and extended from said piercing probe during pipetting operations; and(e) a spring disposed in the opening in the piercing probe guide and arranged to couple said pipetting probe to said piercing probe, wherein said spring urges the piercing probe away from the piercing probe guide along the piercing direction.2. The apparatus according to claim 1 , wherein the spring has a spring constant selected such that said pipetting probe does not extend from the through-hole when said piercing probe is fully withdrawn from said wells claim 1 , and translation of said pipetting probe towards said wells results in cotranslation of said piercing probe and delivery of sufficient force to remove seals on said wells.3. The apparatus according to claim 2 , wherein the spring constant is selected such that further continued translation past the maximal distance of travel of said ...

METHODS FOR EVALUATION OF THE EFFECTIVENESS OF A DRUG OR DRUG CANDIDATE IN TREATING AN INFLAMMATORY BOWEL DISEASE BY USE OF A MULTIPLEXED ASSAY KIT COMPRISING VARIOUS BIOMARKERS

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention. 118.-. (canceled)19. A multiplexed assay kit used to evaluate the efficacy of a treatment regimen in a patient diagnosed with inflammatory bowel disease , wherein said kit comprises an assay cartridge for conducting a plurality of assays , wherein said cartridge is configured to measure a level of a plurality of biomarkers in a patient sample , said plurality of biomarkers comprises soluble TNF receptor II (sTNFRII) and MIP-1beta , and at least one additional biomarker comprising eotaxin , sIL-6R , MCP-1 , RANTES , and combinations thereof.20. The kit of wherein the multi-well assay plate is capable of communicating with a processor claim 19 , the processor configured to determine a ratio of sTNFRII to MIP-1 beta in samples from said patients versus people not diagnosed with inflammatory bowel disease.21. The kit of claim 19 , further comprising in one or more vials claim 19 , containers claim 19 , or compartments claim 19 , a set of labeled detection antibodies specific for said plurality of biomarkers.22. The kit of claim 19 , wherein said kit is further configured to compare said level to a level of a normal control.23. The kit of claim 19 , wherein said at least ...

AN ATTENUATED EHEC AND CLOSTRIDIAL TOXINS TCDA AND TCDB BASED VACCINE FOR CLOSTRIDIUM DIFFICIL ASSOCIATED DISEASE (CDAD)

Provided are novel methods for expressing antigens in a vaccine vector strain, a live oral vaccine designed to prevent clostridium difficile-associated disease and methods for delivering antigens to the mucosal immune system of a subject. 1Escherichia Coli. A method for delivering an antigen to the mucosal immune system of a subject comprising administering to the subject a composition comprising a live attenuated Enterohemorrhagic (EHEC) comprising an antigen of another pathogen.2Clostridium Difficile.. The method of claim 1 , wherein the antigen of another pathogen is an antigen of3Clostridium DifficileEscherichia Coli. A method of treating claim 1 , preventing or ameliorating a Associated Disease comprising administering to a subject a composition comprising a live attenuated Enterohemorrhagic (EHEC) comprising an antigen of another pathogen claim 1 , wherein the antigen is delivered to the mucosal immune system of the subject.4Clostridium Difficile.. The method of claim 3 , wherein the antigen of another pathogen is an antigen of5Clostridium DifficileClostridium difficile.. The method of claim 3 , wherein the Associated Disease comprises diarrhea claim 3 , fever claim 3 , nausea claim 3 , loss of appetite claim 3 , or abdominal pain in an individual infected with6Escherichia coliClostridium difficileClostridium difficile. A method of inducing an immune response in a subject in need thereof claim 3 , comprising administering to the subject an immunologically-effective amount of a live attenuated Enterohemorrhagic vector comprising a cell binding domain of TcdA toxin of or an antigenic fragment thereof and a cell binding domain of TcdB toxin of or an antigenic fragment thereof.7. The method of claim 6 , wherein the TcdA and TcdB are surface bound.816-. (canceled) This application claims priority to U.S. Provisional Patent Application No. 61/712,923, filed Oct. 12, 2012, which is hereby incorporated by reference in its entirety.The present invention was made with ...

METHOD AND SYSTEM FOR INSTALLING AND RUNNING UNTRUSTED APPLICATIONS

Securely storing, installing, or launching applications. A method includes determining a trust characteristic or a license characteristic assigned to an application. When the trust characteristic or the license characteristic meets or exceeds a predetermined trust condition or a predetermined license condition, then the method includes at least one of storing, installing or launching the application in a first, more secure operating system while preventing the application from, being at least one of stored, installed or launched in a second, less secure operating system. When the trust characteristic or the license characteristic does not meet or exceed the predetermined trust condition or the predetermined license condition, then the method includes at least one of storing, installing or launching the application in the second less secure operating system while preventing the application from being at least one of stored, installed or launched in the first, more secure operating system. 1. A computer system comprising:one or more processors; and determining a trust characteristic or a license characteristic assigned to an application;', 'when the trust characteristic or the license characteristic assigned to the application meets or exceeds a predetermined trust condition or a predetermined license condition, then at least one of storing, installing or launching the application in a first, more secure operating system while preventing the application from, being at least one of stored, installed or launched in a second, less secure operating system; and', 'when the trust characteristic or the license characteristic assigned to the application does not meet or exceed the predetermined trust condition or the predetermined license condition, then at least one of storing, installing or launching the application in the second less secure operating system while preventing the application from being at least one of stored, installed or launched in the first, more secure ...

MEMORY ASSIGNMENT FOR GUEST OPERATING SYSTEMS

Techniques for memory assignment for guest operating systems are disclosed herein. In one embodiment, a method includes generating a license blob containing data representing a product key copied from a record of license information in the host storage upon receiving a user request to launch an application in the guest operating system. The method also includes storing the generated license blob in a random memory location accessible by the guest operating system. The guest operating system can then query the license blob for permission to launch the application and launching the application in the guest operating system without having a separate product key for the guest operating system. 1. A method for memory assignment for a guest operating system supported by a host operating system on a host computing device having a host storage holding records of license information accessible only to the host operating system , the method comprising:receiving a request to launch an application in the guest operating system; and generating, based on a record of license information stored in the host storage, a license blob containing data representing a product key copied from the record of license information;', 'determining a random memory location within a range of memory allocated to the guest operating system by the host operating system; and', 'writing the generated license blob to the determined random memory location for access by the guest operating system to launch the application, thereby preventing relaunching the application in a new guest operating system on a new host computing device using the same license blob when data in the range of memory allocated to the guest operating system on the host computing device is copied to a new range of memory that is allocated to the new guest operating system on the new host computing device., 'in response to receiving the request, at the host operating system,'}2. The method of wherein generating the license blob also ...

SECURE SHARING OF LICENSE DATA IN COMPUTING SYSTEMS

Techniques for secure sharing of data in computing systems are disclosed herein. In one embodiment, a method includes when exchanging data between the host operating system and the guest operating system, encrypting, at a trusted platform module (TPM) of the host, data to be exchanged with a first key to generate encrypted data. The method also includes transmitting the encrypted data from the host operating system to the guest operating system and decrypting, at the guest operating system, the transmitted encrypted data using a second key previously exchanged between the TPM of the host and a virtual TPM of the guest operating system. 1. A method of secure data exchange between a host operating system and a guest operating system supported by the host operating system on a host , the method comprising:receiving, at a guest operating system, a request to launch an application in the guest operating system; and transmitting, to the host operating system, a license request for license information corresponding to the application;', 'receiving, from the host operating system, a license blob from the host operating system, the license blob containing encrypted license information of the application;', 'decrypting, at the guest operating system, the received license blob using a key previously exchanged between a cryptoprocessor of the host and a virtual cryptoprocessor of the guest operating system; and', 'launching the application in the guest operating system based on the license information in the decrypted license blob, thereby enabling secured license data exchange between the host and guest operating systems., 'in response to receiving the request,'}2. The method of wherein the virtual cryptoprocessor at the guest operating system is bound to the cryptoprocessor at the host by a binding key.3. The method of claim 1 , further comprising:generating the key at the cryptoprocessor of the host during initialization of the guest operating system; andsharing the key ...

Electrochemiluminescence flow cell and flow cell components

An electrochemiluminescence cell comprising an electrode capable of inducing an electrochemiluminescence-active species to electrochemiluminesce. The electrode is preferably made of rhodium, iridium or an alloy of platinum, rhodium or iridium alloyed with an alloy material comprising a transition element. The electrode may be used as counter electrode and/or as a working electrode in the electrochemiluminescence cell. The cell preferably includes a counter electrode and a support attached to the counter electrode. The support comprises a transparent portion in optical registration with the working electrode. The counter electrode may include one or more field extending elements interposed between the transparent portion and the working electrode. The field extending element is preferably a ladder or a grid.

SYSTEMS AND METHODS FOR PERFUSION CONTROL IN BIOREACTORS

Systems () and methods for perfusion control in a bioreactor () are provided. The system () comprises a media container () connected to the bioreactor () and weighing scales () measure weight of the bioreactor () and the media container (). A plurality of controllers () are connected to the weighing scales and configured to continuously feed the media from media container () to the bioreactor () at a user defined rate using a motor pump (). A filter () is provided to receive feed from the bioreactor () through a recirculation line () and a permeate flow line () is connected to the filter () to flow out the permeate from the filter (). When weight of the bioreactor () goes beyond the upper (U) or lower (L) permissible weight limit, a controller () connected to the weighing scale of the bioreactor () sends a signal to operate the permeate motor pump () either to flow out the permeate from the filter () or to stop the motor pump (). 1. A perfusion control system for a bioreactor , the system comprising:at least one controller;a media container adapted to store reaction media;a bioreactor fluidically connected to the media container via a media feed line;at least one weighing device configured to measure the weight of the media container and the weight of the bioreactor;a filter fluidically connected to the bioreactor via a recirculation line and via a retentate line;a permeate line fluidically connected to the filter and configured to accept a flow of the permeate from the filter; andat least one pump provided in each of the media feed line, recirculation line, and permeate line configured to provide flow of the reaction fluid along any one or more of said feed, recirculation, and permeate lines; receive signals from the weighing device(s) indicative of the weight of the media container and the bioreactor,', 'send a control signal to the media feed pump to feed media to the bioreactor at a defined flow rate, and', 'send a control signal corresponding to the weight of ...

Assay modules having assay reagents and methods of making and using same

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

Production of tacrolimus (fk-506) using new streptomyces species

The invention relates to a new microorganism Streptomyces glaucescens MTCC 5115 and a process for producing the immunosuppressant agent, tacrolimus (FK-506) utilizing the new microorganism Streptomyces glaucescens MTCC 5115. The invention also relates to pharmaceutical compositions that include the tacrolimus (FK-506) and use of said compositions for treatment or prevention of the transplantation rejection of organs or tissues such as heart, kidney, liver, medulla ossium, skin, etc.

Leader sequence for higher expression of recombinant proteins

The present invention relates to the leader sequence for higher expression of recombinant proteins. The invention further relates to the process for preparation of insulin and insulin analogues using leader sequence. The leader peptides significantly increase the expression of pre-proinsulin. The present invention also relates to the protein sequences prepared by fusion of fragments with the leader sequences of the present invention. The invention is demonstrated by preparing and Insulin and its analogues using said leader sequences.

Registering a mobile terminal in an area of overlapping cell coverage by first and second networks

A method is provided of registering a mobile terminal in an area of overlapping cell coverage by first and second networks for wireless mobile telecommunications. The networks are of different types. The method comprises: storing an identifier of the mobile terminal; storing in a controller a first record of in which cell or group of cells the mobile terminal is located in the first network and a second record of in which cell or group of cells the mobile terminal is located in the second network; and providing the mobile terminal with information of both records and said identifier.

Improved methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Assay modules having assay reagents and methods of making and using same

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE

Una forma de dosificación parenteral estable de una solución acuosa, estable, lista para inyectar, de acetato de cetrorelix. La presente también se relaciona con un dispositivo de inyección precargado con la solución acuosa, estable, estéril, lista para inyectar, de acetato de cetrorelix. La presente se relaciona con un método para inhibir picos prematuros de la hormona luteinizante en mujeres sometidas a una estimulación ovárica controlada que comprende una forma de dosificación parenteral estable con una solución acuosa, estable, estéril, lista para inyectar, de acetato de cetrorelix. Reivindicación 1: Una forma de dosificación parenteral, caracterizada porque comprende una solución acuosa estable que comprende: (i) cetrorelix o una sal farmacéuticamente aceptable del mismo; y (ii) una impureza de la fórmula (1) a una cantidad menor que 1% p/v de base de cetrorelix. A stable parenteral dosage form of a stable, ready-to-inject, aqueous solution of cetrorelix acetate. This also relates to an injection device pre-filled with the stable, sterile, ready-to-inject aqueous solution of cetrorelix acetate. The present invention relates to a method of inhibiting premature luteinizing hormone surges in women undergoing controlled ovarian stimulation comprising a stable parenteral dosage form with a stable, sterile, ready-to-inject aqueous solution of cetrorelix acetate. Claim 1: A parenteral dosage form, characterized in that it comprises a stable aqueous solution comprising: (i) cetrorelix or a pharmaceutically acceptable salt thereof; and (ii) an impurity of formula (1) at an amount of less than 1% w/v cetrorelix base.

Assay modules having assay reagents and methods of making and using same

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

Assay cartridge valve system

Fermentation process for the preparation of pravastatin

The invention relates to a fermentation process for the preparation of substantially pure pravastatin. The process provides a method of producing pravastatin by microbial hydroxylation of compactin (ML-236B) by maintaining a concentration of compactin at not less than 300 ~g /ml during the process. The process produces substantially pure pravastatin with reduced related impurities. The invention also relates to pharmaceutical compositions that include the substantially pure pravastatin.

Assay apparatuses, methods and reagents

We describe apparatuses, systems, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi--well plate assay format. For example, they may be used for automated analysis of particulates in air and/or liquid samples derived therefrom in environmental monitoring.

Fermentation process for the preparation of pravastatin

The invention relates to a fermentation process for the preparation of substantially pure pravastatin. The process provides a method of producing pravastatin by microbial hydroxylation of compactin (ML-236B) by maintaining a concentration of compactin at not less than 300 µg /ml during the process. The process produces substantially pure pravastatin with reduced related impurities. The invention also relates to pharmaceutical compositions that include the substantially pure pravastatin.

Protein for treatment of inflammatory diseases

Atorvastatin pharmaceutical compositions

The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts.

Inhibit handover for real-time calls in GPRS systems

A mobile telephone system providing general packet radio service (GPRS) includes a radio network controller (RNC) (2A) and/or a base station controller (BSC) and an associated serving GPRS support node (10A) for each domain. The RNCs (2A) and the SGSNs (10A) are interconnected by an Internet protocol (IP) network. When a mobile telephone (6A) moves from one domain to another, the RNC, in the new domain, takes over handling the mobile telephone. The current SGSN (10A) has a detector (20) which detects whether the existing transmission is a real-time transmission and, if it is, a diverter (22) comes into operation to couple the RNC in the new domain to the current SGSN (10A) rather than its associated SGSN (10A). When the call ends, the current SGSN (10A) handsover the call to the SGSN (10A) in the new domain. This procedure ensures minimal interruption to real-time services by keeping the call anchored to the current SGSN (10A).

Assay cartridges and methods of using the same

Assay cartridges are described that have a detection chamber, preferably having integated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Adso described are kits including such cartridges and a cartridge reader configured to analyze an assay con-ducted using an assay cartridge.

Atorvastatin pharmaceutical compositions

The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts.

Assay apparatuses, methods and reagents

method and apparatus for handover with data forwarding from source to target evolved node-b in a wireless telecommunications network

According to an aspect of the invention, a method for handover of a mobile terminal from a source node to a target node in a wireless telecommunications network includes the steps of making data forwarding of fresh data optional irrespective of the RLC mode, which may involve RLC-UM or RLC-AM bearers. The method may include providing an explicit instruction to the mobile terminal for each bearer on whether a bearer is subject to data forwarding or not. This may then be used by the mobile terminal to handle the buffered packets and PDCP SNs.

Method and apparatus for radio link failure recovery in a wireless communication network

In a wireless network, for example, an LTE network, the context information relating to a mobile terminal UE is transmitted to a plurality of network nodes eNB 2, 3 and 4 from a source network node, eNB 1. One of the eNB 2 is a handover target node and also reserves resources for the UE in anticipation of receiving it after handover. The other eNBs 3 and 4 do not reserve resources. In the event of radio link failure, the UE may attach to one of the designated eNBs3 and 4 that have not reserved resources, but that do recognize the UE because they have received its context. The method reduces the likelihood of the UE needing to go via the time consuming IDLE state while only reserving resources at a handover target eNB.

Protein for treatment of inflammatory diseases.

La presente invención se refiere a una lectina para su uso en el tratamiento, reducción de la progresión y curación de la inflamación en un sujeto que lo necesite. También se describen composiciones farmacéuticas que comprenden dicha lectina. La lectina puede comprender una secuencia de aminoácidos que tiene la secuencia de la SEQ ID NO: 1 o al menos 60 % de homología con la SEQ ID NO: 1.

Encryption in a wireless telecommunications

Assay apparatuses, methods and reagents

We describe apparatuses, systems, method, reagents, and kits for conducting assays as well as process for their preparation. They are particularly well suited for conducting automated sampling, sample preparation, and analysis in a multi-well plate assay format. For example, they may be used for automated analysis of particulates in air and/or liquid samples derived therefrom in environmental monitoring.

Assay cartridges and methods of using the same

Assay cartridges are described that have a detection chamber, preferably having integrated electrodes, and other fluidic components which may include sample chambers, waste chambers, conduits, vents, bubble traps, reagent chambers, dry reagent pill zones and the like. In certain embodiments, these cartridges are adapted to receive and analyze a sample collected on an applicator stick. Also described are kits including such cartridges and a cartridge reader configured to analyze an assay conducted using an assay cartridge.

Improved methods for conducting multiplexed assays

The invention relates to methods for conducting solid-phase binding assays. One example is an assay method having improved analyte specificity where specificity is limited by the presence of non-specific binding interactions.

Assay modules having assay reagents and methods of making and using same

We describe assay modules (e.g., assay plates, cartridges, multi-well assay plates, reaction vessels, etc.), processes for their preparation, and method of their use for conducting assays. Reagents may be present in free form or supported on solid phases including the surfaces of compartments (e.g., chambers, channels, flow cells, wells, etc.) in the assay modules or the surface of colloids, beads, or other particulate supports. In particular, dry reagents can be incorporated into the compartments of these assay modules and reconstituted prior to their use in accordance with the assay methods. A desiccant material may be used to maintain and stabilize these reagents in a dry state.

Method and apparatus for handover by implementing pre-handover indication messages for a preferred target node in wireless telecommunication networks

A method for handover of a mobile terminal from a source node to a target node in a wireless telecommunications network, including the steps of: adding an indication in the preparation phase by which source node indicates to the target node if it is the one preferred or not. If a target node is not the one preferred but is still selected by the UE, it may indicate this to the source node as by a specific new message that comes earlier in the handover process than a message requesting the source node to release resources following successful handover to a new node. The source node can then in this case cancel handover preparations to other target nodes earlier and also start data forwarding where applicable earlier.